Wockhardt says FDA inspected US unit in March quarter

Tags: Companies
The US Food and Drug Administration (FDA) has made some observations about the production process of the US unit of Indian generic drugmaker Wockhardt Ltd, the company said on Tuesday.

The FDA last year banned Wockhardt's two Indian units from exporting to the United States, its biggest market, citing quality lapses in the manufacturing process.

Managing Director Murtaza Khorakiwala told an analysts briefing the FDA had inspected the company's Chicago-based Morton Grove Pharmaceuticals unit, which accounts for more than 50 percent of its sales in the United States, in the March quarter. He did not give further details.

"It's difficult to say what kind of position the FDA will take but according to us the inspection was not a very negative inspection," Khorakiwala said.

Wockhardt on Monday reported a 78 percent drop in net profit for the March quarter, as it continues to reel under the U.S. and U.K. import bans due to manufacturing quality lapses.

In November, the U.S. Food and Drug Administration (FDA) issued an import alert, effectively a ban, against Wockhardt's Chikalthana plant in western India. The FDA had imposed a ban on the company's Waluj plant in May.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Investigating a crime after three decades is little more than a gimmick

    That communal riots and their aftermath are the easiest stick to beat any opposition with, and have tremendous emotive and therefore vote-catching abi

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Urs Schoettli

It’s time for Japan to step out of its shell

The execution of a Japanese hostage by ISIS has sho­cked ...

Zehra Naqvi

The urge to tell stories

One wants to tell a story, like Scheherzade, in order ...

Bubbles Sabharwal

Truth about truth

The question to ponder is, “is it the truth because ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture